Basic Information
Enrylaze
Regulatory Information
EMEA/H/C/005917
September 15, 2023
July 20, 2023
October 5, 2023
Company Information
Ireland
Fifth Floor Waterloo Exchange Waterloo Road D04 E5W7 Dublin 4
JAZZ PHARMACEUTICALS IRELAND LIMITED
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.
Overview Summary
Enrylaze is a cancer medicine used in adults and children aged one month and older to treat acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL), cancers of white blood cells called lymphoblasts. It is used in combination with other medicines in patients who have developed hypersensitivity (allergic reactions) or silent inactivation to E. coli-derived asparaginase, another cancer medicine. Silent inactivation means development of antibodies (proteins) that reduce the effectiveness of asparaginase without resulting in apparent allergy symptoms. Enrylaze contains the active substance crisantaspase.